Rezolute (NASDAQ:RZLT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Rezolute (NASDAQ:RZLT) had its target price increased by stock analysts at Citizens Jmp from $9.00 to $17.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price would suggest a potential upside of 73.12% from the stock’s current price.

Several other research firms have also issued reports on RZLT. Maxim Group raised their price target on shares of Rezolute from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. JMP Securities set a $17.00 price target on shares of Rezolute in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research report on Wednesday, September 3rd. BTIG Research reissued a “buy” rating and issued a $17.00 price target on shares of Rezolute in a report on Thursday, September 18th. Finally, Citigroup reissued an “outperform” rating on shares of Rezolute in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Rezolute Price Performance

Shares of Rezolute stock opened at $9.82 on Wednesday. Rezolute has a fifty-two week low of $2.21 and a fifty-two week high of $10.04. The firm has a fifty day moving average price of $8.38 and a two-hundred day moving average price of $5.92. The company has a market cap of $891.95 million, a PE ratio of -10.12 and a beta of 0.04.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Analysts expect that Rezolute will post -0.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rezolute

Several institutional investors and hedge funds have recently bought and sold shares of the business. Huntleigh Advisors Inc. increased its holdings in Rezolute by 16.7% in the 3rd quarter. Huntleigh Advisors Inc. now owns 17,500 shares of the company’s stock valued at $164,000 after buying an additional 2,500 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Rezolute in the 3rd quarter valued at $1,130,000. Nisa Investment Advisors LLC acquired a new stake in shares of Rezolute in the 3rd quarter valued at $555,000. Altfest L J & Co. Inc. acquired a new stake in shares of Rezolute in the 3rd quarter valued at $301,000. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Rezolute in the 2nd quarter valued at $7,766,000. Institutional investors own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.